Detalles de la búsqueda
1.
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Blood
; 139(26): 3722-3731, 2022 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35439295
2.
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 26(6): 1099-1105, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32165327
3.
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Blood
; 132(8): 777-781, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29914976
4.
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Am J Hematol
; 95(7): 775-783, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32243637
5.
Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease.
Biol Blood Marrow Transplant
; 25(6): 1247-1252, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30711778
6.
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Haematologica
; 108(12): 3433-3437, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37259597
7.
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.
Br J Haematol
; 190(6): e332-e335, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32567674
8.
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
Am J Hematol
; 94(4): E117-E116, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30663774
9.
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol
; 94(8): E209-E213, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31056762
10.
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.
Bone Marrow Transplant
; 57(12): 1765-1773, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36064752
11.
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
Blood Adv
; 6(1): 37-45, 2022 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34649272
12.
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Leuk Lymphoma
; 63(12): 2918-2922, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35811554
13.
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.
Transplant Cell Ther
; 27(1): 57.e1-57.e8, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32980545
14.
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
JAMA Oncol
; 7(7): 993-1003, 2021 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33956047
15.
Where does transplant fit in the age of targeted therapies?
Hematology Am Soc Hematol Educ Program
; 2019(1): 287-293, 2019 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31808860
16.
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.
Blood Adv
; 5(18): 3563-3567, 2021 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34474474
17.
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
Blood Adv
; 4(19): 4869-4872, 2020 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33031539
Resultados
1 -
17
de 17
1
Próxima >
>>